Developer docs
API playgroundTry for free, no card

Search company profiles

Admetsys

Full company profile

uuid0005jir

Namestring
Admetsys
Legal namestring
Admetsys Corporation
Websiteurl
admetsys.com
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical robotics systems, blood glucose monitoring, metabolic control automation, critical care medical devices, continuous biosensing technology
Industry2 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Analytical Laboratory Instrument Manufacturing334516
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Critical Care Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Admetsys generates revenue through the sale of its PrecisionOne™ clinical automation controller and Intravenous Laboratory™ continuous blood diagnostics system to hospitals and healthcare systems. The device is a capital equipment with consumable cartridge components. Revenue model appears to be hardware sales with potential recurring consumables revenue from replacement sensor cartridges. CE Mark approved for commercial use in EU/EEA; FDA clearance pending for US market.

admetsys.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1PrecisionOne™
Description

Clinical automation controller that captures data from biosensors, constructs AI models of patient metabolism in real time, and autonomously regulates patient glucose through optimized insulin and dextrose therapy.

admetsys.com
+3 more records
Core offering1 text field

Admetsys develops and sells an AI-powered clinical robotics system for blood analysis and metabolic control in critical care and surgical settings. The platform combines the PrecisionOne™ Clinical Automation Controller, which builds a real-time AI model of each patient's metabolism to autonomously regulate glucose via optimized insulin and dextrose infusion, with the Intravenous Laboratory™ (IVLab™), a cartridge-based extracorporeal biosensor providing up to 7 days of continuous zero-blood-loss measurement of glucose, lactate, hematocrit, and temperature (expandable to 20 analytes). The system is sold to hospitals and healthcare systems as capital medical-device hardware complemented by recurring consumable biosensor cartridges.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 34% reduction in mortality with glucose control
+9 more records
Product overview1 text field

Admetsys offers a unified clinical robotics system for blood analysis and metabolic control in critical care and surgery settings. The system consists of two integrated products: PrecisionOne™ (clinical automation controller) and Intravenous Laboratory™ (real-time continuous blood diagnostics). PrecisionOne captures biosensor data and constructs AI models of patient metabolism to autonomously regulate glucose, while Intravenous Laboratory provides continuous extracorporeal blood sensing for early sepsis detection. These products work together as a combined platform enabling high-precision automation that is adaptive to each individual patient and automatically implements clinician-set goals.

Product and service2 records
1PrecisionOne™ Clinical Automation Controller
CategoryClinical Automation Controller (Critical Care Medical Device)
Description

The PrecisionOne Clinical Automation Controller is an AI-driven medical device for adult critical care and surgical patients in hospital ICU and operating-room settings. It captures data from one or more biosensors, constructs an evolving computational (AI) model of each patient's metabolism in real time, and autonomously regulates patient glucose with zero clinician intervention by directly infusing continuously-optimized insulin and dextrose therapy. It has demonstrated 97% control between 80–125 mg/dL, 100% prevention of hypoglycemia under 70 mg/dL, and a 2.5-hour mean time to normoglycemia across 3 U.S. clinical trials.

2Intravenous Laboratory™ (IVLab™) Continuous Blood Diagnostics
CategoryContinuous Blood Diagnostics System (Critical Care Medical Device Consumable Platform)
Description

The Intravenous Laboratory (IVLab) is a cartridge-based extracorporeal whole-blood biosensing system for adult critical care and surgical patients. It provides zero-blood-loss continuous measurement across 4 analytes (blood glucose, lactate, temperature, hematocrit) expandable to 20 analytes for up to 7 days of continuous biosensing. Lactate measurement enables early detection and mitigation of sepsis, and the IVLab biosensor data informs PrecisionOne's glucose regulation function. It is sold to hospitals as a recurring consumable cartridge platform paired with the PrecisionOne controller.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Glytec's eGlycemic Management System is software for hospital insulin dosing, the closest software analog to Admetsys' autonomous glycemic control. Both target ICU/hospital glucose management with dose-decision automation.

TypeDirect peer
Description

Monarch's EndoTool is a hospital insulin dosing decision-support platform used in critical care. It directly overlaps Admetsys' PrecisionOne use case of automated glycemic management in the ICU.

TypeDirect peer
Description

OptiScan develops continuous glucose monitoring systems for the ICU, comparable to Admetsys' IVLab component. Both provide real-time hospital glucose biosensing intended for critical care glycemic management.

TypeDirect peer
Description

Nova Biomedical manufactures blood gas and hospital glucose analyzers including critical care analyzers. Their StatStrip and hospital blood chemistry platforms overlap with IVLab's continuous ICU biosensing value proposition.

TypeBroad incumbent
Description

Medtronic has a major diabetes franchise (MiniMed AID systems, Guardian CGM) and a hospital infusion pump portfolio. While focused on ambulatory diabetes, the company has the resources and ICU channels to enter autonomous critical care glycemic control.

TypeBroad incumbent
Description

Dexcom is the leading continuous glucose monitor manufacturer and is expanding into hospital/ICU use cases (Dexcom hospital program). Its CGM technology is comparable to the IVLab continuous biosensing function.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the dominant CGM globally and Abbott has hospital-facing diagnostics. As a large diversified medtech incumbent, it is positioned to enter or enable autonomous critical care glycemic management.

TypeBroad incumbent
Description

B. Braun is a global leader in hospital infusion systems (Infusomat, Perfusor) and has its own diabetes care unit. Its installed infusion pump base and ICU relationships make it a potential competitor or partner for Admetsys' closed-loop insulin/dextrose therapy.

TypeEmerging player
Description

Tandem's t:slim X2 with Control-IQ is a leading automated insulin delivery system for ambulatory diabetes. While focused outside the ICU, its closed-loop AID architecture is conceptually adjacent to Admetsys' autonomous dosing model.

TypeEmerging player
Description

Insulet's Omnipod 5 is an automated insulin delivery system for ambulatory diabetes. Its AID technology platform is adjacent to Admetsys' autonomous insulin/dextrose infusion approach, though the clinical setting differs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Admetsys

Critical Care Medical Devicesadmetsys.com

Admetsys firmographics

Firmographics
Name
Admetsys
Legal name
Admetsys Corporation
Website
https://admetsys.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Admetsys industry classification

Industry
Product category
Critical Care Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Clinical robotics systems
  • Blood glucose monitoring
  • Metabolic control automation
  • Critical care medical devices
  • Continuous biosensing technology

Where Admetsys is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Admetsys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Admetsys generates revenue through the sale of its PrecisionOne™ clinical automation controller and Intravenous Laboratory™ continuous blood diagnostics system to hospitals and healthcare systems. The device is a capital equipment with consumable cartridge components. Revenue model appears to be hardware sales with potential recurring consumables revenue from replacement sensor cartridges. CE Mark approved for commercial use in EU/EEA; FDA clearance pending for US market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Admetsys product offering

Product offering

Core offering

Admetsys develops and sells an AI-powered clinical robotics system for blood analysis and metabolic control in critical care and surgical settings. The platform combines the PrecisionOne™ Clinical Automation Controller, which builds a real-time AI model of each patient's metabolism to autonomously regulate glucose via optimized insulin and dextrose infusion, with the Intravenous Laboratory™ (IVLab™), a cartridge-based extracorporeal biosensor providing up to 7 days of continuous zero-blood-loss measurement of glucose, lactate, hematocrit, and temperature (expandable to 20 analytes). The system is sold to hospitals and healthcare systems as capital medical-device hardware complemented by recurring consumable biosensor cartridges.

Product overview

Admetsys offers a unified clinical robotics system for blood analysis and metabolic control in critical care and surgery settings. The system consists of two integrated products: PrecisionOne™ (clinical automation controller) and Intravenous Laboratory™ (real-time continuous blood diagnostics). PrecisionOne captures biosensor data and constructs AI models of patient metabolism to autonomously regulate glucose, while Intravenous Laboratory provides continuous extracorporeal blood sensing for early sepsis detection. These products work together as a combined platform enabling high-precision automation that is adaptive to each individual patient and automatically implements clinician-set goals.

Differentiator

Problem solved

Functional benefit

Brands

  • PrecisionOne™: Clinical automation controller that captures data from biosensors, constructs AI models of patient metabolism in real time, and autonomously regulates patient glucose through optimized insulin and dextrose therapy.
  • Intravenous Laboratory™
  • IVLab™
  • Metabolic Autopilot™

Products and services

  • PrecisionOne™ Clinical Automation Controller The PrecisionOne Clinical Automation Controller is an AI-driven medical device for adult critical care and surgical patients in hospital ICU and operating-room settings. It captures data from one or more biosensors, constructs an evolving computational (AI) model of each patient's metabolism in real time, and autonomously regulates patient glucose with zero clinician intervention by directly infusing continuously-optimized insulin and dextrose therapy. It has demonstrated 97% control between 80–125 mg/dL, 100% prevention of hypoglycemia under 70 mg/dL, and a 2.5-hour mean time to normoglycemia across 3 U.S. clinical trials.
  • Intravenous Laboratory™ (IVLab™) Continuous Blood Diagnostics The Intravenous Laboratory (IVLab) is a cartridge-based extracorporeal whole-blood biosensing system for adult critical care and surgical patients. It provides zero-blood-loss continuous measurement across 4 analytes (blood glucose, lactate, temperature, hematocrit) expandable to 20 analytes for up to 7 days of continuous biosensing. Lactate measurement enables early detection and mitigation of sepsis, and the IVLab biosensor data informs PrecisionOne's glucose regulation function. It is sold to hospitals as a recurring consumable cartridge platform paired with the PrecisionOne controller.

Quantifiable outcome

  • 34% reduction in mortality with glucose control
  • +9 more outcomes

Companies that use Admetsys

Customer profile

Segments1 record

Ideal customer profiles1 record

Admetsys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Admetsys partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Admetsys competitors and assessment

Company assessment

Direct peers

  • Glytec: Glytec's eGlycemic Management System is software for hospital insulin dosing, the closest software analog to Admetsys' autonomous glycemic control. Both target ICU/hospital glucose management with dose-decision automation.
  • Monarch Medical Technologies: Monarch's EndoTool is a hospital insulin dosing decision-support platform used in critical care. It directly overlaps Admetsys' PrecisionOne use case of automated glycemic management in the ICU.
  • OptiScan Biomedical: OptiScan develops continuous glucose monitoring systems for the ICU, comparable to Admetsys' IVLab component. Both provide real-time hospital glucose biosensing intended for critical care glycemic management.
  • Nova Biomedical: Nova Biomedical manufactures blood gas and hospital glucose analyzers including critical care analyzers. Their StatStrip and hospital blood chemistry platforms overlap with IVLab's continuous ICU biosensing value proposition.

Broad incumbents

  • Medtronic: Medtronic has a major diabetes franchise (MiniMed AID systems, Guardian CGM) and a hospital infusion pump portfolio. While focused on ambulatory diabetes, the company has the resources and ICU channels to enter autonomous critical care glycemic control.
  • Dexcom: Dexcom is the leading continuous glucose monitor manufacturer and is expanding into hospital/ICU use cases (Dexcom hospital program). Its CGM technology is comparable to the IVLab continuous biosensing function.
  • Abbott Diabetes Care: Abbott's FreeStyle Libre is the dominant CGM globally and Abbott has hospital-facing diagnostics. As a large diversified medtech incumbent, it is positioned to enter or enable autonomous critical care glycemic management.
  • B. Braun: B. Braun is a global leader in hospital infusion systems (Infusomat, Perfusor) and has its own diabetes care unit. Its installed infusion pump base and ICU relationships make it a potential competitor or partner for Admetsys' closed-loop insulin/dextrose therapy.

Emerging players

  • Tandem Diabetes Care: Tandem's t:slim X2 with Control-IQ is a leading automated insulin delivery system for ambulatory diabetes. While focused outside the ICU, its closed-loop AID architecture is conceptually adjacent to Admetsys' autonomous dosing model.
  • Insulet: Insulet's Omnipod 5 is an automated insulin delivery system for ambulatory diabetes. Its AID technology platform is adjacent to Admetsys' autonomous insulin/dextrose infusion approach, though the clinical setting differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Admetsys social profiles

Digital presence

Admetsys compliance and trust

Trust signal

Compliance2 records

Admetsys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Admetsys leadership team

Management profile

Number of profiles

Profiles3 records

Admetsys funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Admetsys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Admetsys

What does Admetsys do?

Admetsys develops and sells an AI-powered clinical robotics system for blood analysis and metabolic control in critical care and surgical settings. The platform combines the PrecisionOne™ Clinical Automation Controller, which builds a real-time AI model of each patient's metabolism to autonomously regulate glucose via optimized insulin and dextrose infusion, with the Intravenous Laboratory™ (IVLab™), a cartridge-based extracorporeal biosensor providing up to 7 days of continuous zero-blood-loss measurement of glucose, lactate, hematocrit, and temperature (expandable to 20 analytes). The system is sold to hospitals and healthcare systems as capital medical-device hardware complemented by recurring consumable biosensor cartridges.

Is Admetsys a public or private company?

Admetsys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Admetsys founded?

Admetsys was founded in 2010. It employs 1 to 10 people.

Where is Admetsys based?

Admetsys is headquartered in Boston, United States, in the North America region.

How does Admetsys make money?

One revenue line is on record: medical Device Sales.

Who are Admetsys's main competitors?

Direct peers on record are Glytec, Monarch Medical Technologies, OptiScan Biomedical and Nova Biomedical. Broad incumbents are Medtronic, Dexcom, Abbott Diabetes Care and B. Braun. Emerging players are Tandem Diabetes Care and Insulet.

Does Admetsys have an API?

No public API is recorded for Admetsys.

What industry is Admetsys in?

Admetsys's product category is Critical Care Medical Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Providence Business NewsGlenn RobertelliGlenn Robertelli, a 25-year bioexecutive, has led Rhode Island's RI Bio since July 2024, connecting companies like Johnson & Johnson and Amgen with universities and state government. He previously co-founded Admetsys and Intelligen, and has helped secure over $45 million in state investment for lab projects.PR NewswireAdmetsys' FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in HospitalAdmetsys Corporation received FDA Breakthrough Device designation for its automated glucose control and continuous blood diagnostics system, accelerating the device's path to market in the United States. The system uses a patient-adaptive learning algorithm with real-time biosensing to automatically measure blood analytes and deliver precisely optimized insulin and dextrose treatment, representing what the company calls "fully autonomous clinical robotics." The designation highlights the unmet need in critical care, where 80% of patients experience metabolic instability from glucose dysregulation and hospitals face increasing pressures from nursing shortages and escalating demand.PR NewswireAdmetsys Secures CE Mark Approval for PrecisionOne™ Automated Glycemic Control and Continuous Diagnostics SystemAdmetsys Corporation, a Boston-based biomedical technology company, has received CE Mark regulatory approval for its PrecisionOne automated glycemic control and continuous diagnostics system, which provides automated glucose regulation and real-time blood chemistry analysis for critical care patients. The system addresses a critical clinical need, particularly highlighted during COVID-19 where hyperglycemia increases mortality 4-fold in diabetic and 7-fold in non-diabetic hospitalized patients. The CE Mark enables commercial marketing across 32 European countries and other jurisdictions with mutual recognition agreements.CNBCThis tiny chip uses A.I. to control blood sugar levels for critical diabetes patientsAdmetsys, a Boston-based start-up, has developed an AI-driven 'artificial pancreas' chip that automates blood sugar monitoring and insulin or glucose administration for critically ill diabetes patients. The device aims to reduce hospital costs by approximately $8,000 per patient and decrease intensive care stays by alleviating the manual workload on nursing staff. Admetsys has completed three successful clinical trials for U.S. FDA approval and plans further trials in Denmark to secure European regulatory clearance.PoetsandquantsforundergradsRoss Undergrad Fund Makes 1st InvestmentThe Zell Early Stage Fund, an undergraduate venture capital program at the University of Michigan Ross School of Business, has made its inaugural investment of $150,000 into Admetsys, a developer of artificial pancreas technology. This marks the first active investment by the fund since its launch in fall 2015, following 18 months of student instruction and research. The investment highlights the program's success in providing undergraduates with practical venture capital experience previously reserved for MBA students.Zell Lurie InstituteU-M undergrad venture fund makes first investmentThe University of Michigan's Zell Early Stage Fund made its first investment in Admetsys, an artificial pancreas company, with $150,000 of its $250,000 capital. The fund, launched in fall 2015, is modeled after the Wolverine Venture Fund, which has $7 million in assets. The investment could save hospitals money by reducing ICU costs.Medicaldesignandoutsourcing7 companies in the race to make an artificial pancreasBoston-based startup Admetsys has developed an artificial pancreas system designed for hospital settings to automatically control blood glucose levels in diabetic patients. The company has completed three clinical trials and established a collaborative deal with Hospira to utilize its dextrose products and syringe systems within the platform.